NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
September 9, 2026 — CollectionPro highlights a federal IDR win against UnitedHealthcare, where a $72K award went unpaid, leading to court enforcement. Learn about post-award recovery.
September 9, 2026 — New review reveals tumor microenvironment reshapes NK cells into three distinct subsets, offering fresh targets for more precise cancer immunotherapies and better patient outcomes.
September 9, 2026 — RoC Skincare's new Line Smoothing 2-Step Peel Pads offer at-home chemical peel results with patented clinical retinol, no downtime, and under $2 per treatment. Suitable for sensitive skin.
September 8, 2026 — Nanox expands Nanox.ARC distribution in New England via Associated X-Ray Imaging, increasing access to 3D tomosynthesis in outpatient settings.
September 8, 2026 — SS Innovations International (SSII) reports 39.4% revenue growth, 224 SSi Mantra systems installed globally, and eyes US and Europe expansion. Learn about the future of surgical robotics.
September 8, 2026 — VERAXA Biotech appoints Raju Willener as CFO to lead capital strategy and support BiTAC(R) platform development. Read about his experience and impact on VRXA.
September 8, 2026 — Scinai Immunotherapeutics refocuses R&D on NanoAb platform, drops PC111 option, and advances psoriasis program with potential €12M grant. CDMO orders reach $3.1M.
September 8, 2026 — Onco-Innovations advances ONC010 PNKP inhibitor with manufacturing and IND milestones, positioning for clinical trials. Learn about the company's progress and investment potential.
September 8, 2026 — OS Animal Health, a subsidiary of OS Therapies (NYSE: OSTX), presents at Moody Capital Conference, advancing OST-HER2 for canine osteosarcoma. Learn about this innovative immunotherapy.
September 8, 2026 — Discover how laser therapy is improving brain cancer outcomes, with insights from Washington University and CNS Pharmaceuticals. Learn about LITT and its potential.
September 8, 2026 — Quantum BioPharma receives FDA clearance for Phase 2 trial of Lucid-MS, a first-in-class drug for progressive MS that may repair myelin, offering new hope.
September 8, 2026 — Ocumetics starts patient recruitment for Group Two trial of its accommodating IOL, evaluating safety and vision performance. Learn about the next step in this vision tech.
September 8, 2026 — Quantum BioPharma's Lucid-MS gets FDA clearance for Phase 2 trial in progressive MS. First-in-class drug aims to repair myelin, offering new hope for patients.
September 8, 2026 — NanoViricides' Ebola drug trial registered in Africa, dosing imminent. Phase II study of NV-387 Oral Gummies may offer new treatment for Ebola and Mpox.
September 8, 2026 — Nutriband gets USPTO Notice of Publication for trademarks on its abuse-deterrent fentanyl patch with AVERSA technology, a step toward US market entry.
September 8, 2026 — Quantum BioPharma's Lucid-MS gets FDA clearance to start Phase 2 trial for multiple sclerosis. First-in-class PAD2 inhibitor targets demyelination. Learn more.
September 8, 2026 — Quantum BioPharma's Lucid-MS gets FDA clearance for Phase 2 MS trial, targeting demyelination. A potential breakthrough in multiple sclerosis treatment.
September 8, 2026 — Quantum BioPharma gets FDA clearance for phase 2 trial of Lucid-MS in multiple sclerosis. Rodman & Renshaw initiates coverage with Buy rating and $8 target.
September 8, 2026 — Tonix Pharmaceuticals promotes Thomas Englese to CCO to lead commercialization of TONMYA for fibromyalgia, expanding patient access and driving growth.
September 8, 2026 — Survivor of grizzly attack and Stage 4 cancer launches BRYTR DAYS, a once-daily nutritional drink for real life. Learn how the Three Rs shape its formula.